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Paediatric UK demyelinating disease longitudinal
study (PUDDLS)
Michael Absoud1,2*, Carole Cummins1, Wui K Chong3, Christian De Goede4, Katharine Foster5, Roxanna Gunny3,
Cheryl Hemingway6, Philip Jardine7, Rachel Kneen8, Marcus Likeman9, Ming J Lim10, Mike Pike11, Naomi Sibtain12,
William P Whitehouse13 and Evangeline Wassmer2
Abstract
Background: There is evidence that at least 5% of Multiple sclerosis (MS) cases manifest in childhood. Children with
MS present with a demyelinating episode involving single or multiple symptoms prior to developing a second event
(usually within two years) to then meet criteria for diagnosis. There is evidence from adult cohorts that the incidence
and sex ratios of MS are changing and that children of immigrants have a higher risk for developing MS. A paediatric
population should reflect the vanguard of such changes and may reflect trends yet to be observed in adult cohorts.
Studying a paediatric population from the first demyelinating event will allow us to test these hypotheses, and may
offer further valuable insights into the genetic and environmental interactions in the pathogenesis of MS.
Methods/Design: The Paediatric UK Demyelinating Disease Longitudinal Study (PUDDLS) is a prospective longitudinal
observational study which aims to determine the natural history, predictors and outcomes of childhood CNS
inflammatory demyelinating diseases. PUDDLS will involve centres in the UK, and will establish a cohort of children
affected with a first CNS inflammatory demyelinating event for long-term follow up by recruiting for approximately 5
years. PUDDLS will also establish a biological sample archive (CSF, serum, and DNA), allowing future hypothesis driven
research. For example, the future discovery of a biomarker will allow validation within this dataset for the evaluation of
novel biomarkers. Patients will also be requested to consent to be contacted in the future. A secondary aim is to
collaborate internationally with the International Paediatric Multiple Sclerosis Study Group when future collaborative
studies are proposed, whilst sharing a minimal anonymised dataset. PUDDLS is the second of two jointly funded
studies. The first (UCID-SS) is an epidemiological surveillance study that already received ethical approvals, and started
on the 1st September 2009. There is no direct patient involvement, and UCID-SS aims to determine the UK and Ireland
incidence of CNS inflammatory demyelinating disorders in children under 16 years.
Discussion: A paediatric population should reflect the vanguard of MS epidemiological changes and may reflect
trends yet to be observed in adult MS cohorts. The restricted window between clinical expression of disease and
exposure to environmental factors in children offers a unique research opportunity. Studying a paediatric
population from the first demyelinating event will allow us to investigate the changing epidemiology of MS, and
may offer further valuable insights into the genetic and environmental interactions in the pathogenesis of MS.
Background
Introduction
CNS inflammatory demyelinating diseases (CIDD) are
rare childhood disorders but may culminate in physical
and cognitive disability or ultimately be diagnosed as
Multiple Sclerosis (MS). MS is a chronic inflammatory
demyelinating disease of the CNS characterized by mye-
lin loss, axonal degeneration and, often, progressive neu-
rological dysfunction, that is usually relapsing remitting
at onset. The incidence of childhood CIDD is unknown,
and the UK and Ireland Childhood Inflammatory
Demyelination Surveillance Study (UCID-SS) is already
underway to determine this. At the first presentation of
a CNS inflammatory demyelinating event, children are
diagnosed with either an acute disseminated encephalo-
myelitis (ADEM), optic neuritis, transverse myelitis, or
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another clinically isolated episode (CIS). Children who
present with a CNS inflammatory demyelinating episode
involving single or multiple symptoms may later present
with a second event (majority usually within two years)
to then meet criteria for MS diagnosis [1]. There is evi-
dence that at least 5% of MS cases manifest in child-
hood [2]. It is not clear at the first onset of symptoms
which children will go on to develop MS.
Prospective studies are required
The available literature on paediatric MS, is primarily
limited to smaller case series and larger retrospective
reviews of established adult MS populations [3-16]. The
International Paediatric MS Study Group, (http://www.
ipmssg.org) have recently published consensus defini-
tions of paediatric CNS inflammatory demyelinating dis-
orders and MS to help facilitate uniformity in future
research [17]. Evidence for differences in natural history
of childhood onset MS [18] are also primarily derived
from retrospective cohorts, as are studies linking envir-
onmental factors (EBV infections or Vitamin D defi-
ciency) with possible MS development [19]. The risk of
relapse in children and hence the risk of developing MS
may be geographically different [1]. There is hence an
urgent need for prospective population based studies to
further understand clinical, radiological, and pathobiolo-
gical features as well as outcome of childhood onset
inflammatory demyelinating disease.
Paediatric cohort may reveal new trends
Various new trends in adult MS have been reported
(reviewed in ref [20]), which include geographic rising
rate of MS, and a rising female to male sex ratio by year
of birth [21]. There is evidence that Indian and Pakistani
immigrants who entered England younger than 15 had a
higher risk of developing MS than those that entered
after this age [22]. The vanguard of any change in
trends in the epidemiology of MS is likely to be evident
in a paediatric population. Genetic epidemiology to date
supports the dual role of “nature and nurture” in MS
pathobiology [20]. As such paediatric cohorts can also
offer further valuable insights into the genetic and envir-
onmental interactions in the pathogenesis of MS. The
corner stone of cohorts that are likely to be able to
address complex disorders such as MS, depend on the
availability of biological sample with comprehensive
databases with clinical information.
New criteria for diagnosis for paediatric MS require
evaluation
At first presentation of CIDD, children are diagnosed
with optic neuritis, transverse myelitis, other clinically
isolated episodes (CIS) or acute disseminated encephalo-
myelitis (ADEM). The newly proposed consensus
definitions [17] for CIDD are operational and require
evaluation in prospectively followed up cohorts. For iso-
lated monophasic syndromes, normal MRI and cere-
brospinal fluid (CSF) are thought to predict a very low
risk for development of MS in adults [23]. However the
same may not be true for children. In addition the dif-
ferential diagnosis for childhood demyelinating disease
and MS (documented in exclusion criteria) is much
wider than that in adults. Furthermore, MRI criteria
used in adults to diagnose MS e.g. MRI McDonald cri-
teria may not be valid in children [24-26]. The utilisa-
tion of revised McDonald criteria [27] and others
including the KIDMUS MRI criteria [10] for paediatric
MS need to be validated in new cohorts.
McDonald et al. [27] criteria:
Three of: 1) ≥ 9 white matter lesions or 1 gadolinium
enhancing lesion, 2) ≥ 3 periventricular lesions, 3) 1 jux-
tacortical lesion, 4) an infratentorial lesion.
KIDMUS [10] criteria:
All of: ≥ 1 lesion perpendicular to long axis of corpus
callosum; sole presence of well defined lesions
No available biomarker for MS
In line with adult based studies [28], there is no cur-
rently available biomarker that fulfils the criteria of a
surrogate endpoint in MS in children. Current routine
tests including CSF oligoclonal bands, lack sensitivity
and specificity in individuals presenting with a first CNS
inflammatory demyelinating event. A precondition for
the identification of biomarkers is a well described and
prospectively followed clinical cohort and the availability
of stored tissue linked to relevant clinical information.
Early diagnosis allows for early treatment
For relapses or attacks of MS, corticosteroids are the
mainstay of treatment. Early initiation of “disease modi-
fying agents”, such as beta interferon and glatiramer
acetate appears to be of benefit in adults. Thus, it is
more critical than ever to accurately diagnose MS as
early as possible. However, very little is published on the
use of interferon in children [29-33]. The determination
of the longitudinal outcome of the first CNS inflamma-
tory demyelinating episode in children is an essential
pre-requisite for the design of any prevention or treat-
ment trials. Prediction of outcome at an early stage is
critical to quantify the risk to benefit ratio of any
intervention.
The need to know the extent of disease burden
Furthermore, identifying the natural history and out-
comes of paediatric MS in the UK has major implica-
tions when planning service provisions, where there is
evolving evidence of lack of awareness, and patchy ser-
vice provision. At the Paediatric MS meeting, London
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November 2007 (attended by families and multidisci-
plinary professionals) there was a call for a better under-
standing of long-term outcomes including quality of life,
cognitive, adaptive behavioural and functional skills,
neuropsychiatric symptoms, and treatment effects for
children presenting with CNS inflammatory
demyelination.
Context of study in relation to current practice
Children with CNS inflammatory demyelination are
most often routinely seen by a Paediatric Neurologist as
part of clinical care in order to provide expert advice
and management. In line with guidelines by the Interna-
tional Paediatric MS Group, demyelination clinics have
been set up in several Tertiary Centres by paediatric
neurologists with an interest in these conditions. This
led to the UK and Ireland Paediatric CNS Inflammatory
Demyelination Working Group being set up, providing a
steering committee for future collaborative studies, net-
working, future direction, writing clinical guidelines and
future grant applications. As a result, the majority of
these children are seen in these specialist centres where
they will be recruited.
Study aims and objectives
PUDDLS aims to establish if prognostic factors for
relapse of CNS inflammatory demyelination (and hence
risk of progression to MS) can be identified for UK chil-
dren (Figure 1). PUDDLS is a prospective UK based
study with the following objectives to:
1. Identify features (clinical, epidemiological, imaging,
pathophysiolgical tests such as oligoclonal bands) that
may predict which children are more likely to relapse
and develop MS, whilst assessing the validity and utility
of the new consensus definitions for childhood CNS
inflammatory demyelination and of proposed MRI
criteria.
2. Establish outcomes for children, for an initial period
of up to five years depending on when the case was
recruited (minimum 6 months follow up).
3. Describe disease modifying therapy usage, efficacy,
and adverse effects.
4. Provide a platform for future a) identification of
biological markers in MS, b) genetic studies and c)
hypothesis driven biological studies; by storing blood
and CSF samples already taken at the time of first
demyelinating event (currently in 7 participating
centres).
5. Ensure that long term outcomes of childhood
demyelinating disease are as complete as possible by
flagging patients with their consent with the NHS Infor-
mation Centre [Medical Research Information Service
(MRIS)] which will allow them to be traced in future via
their G.P.s (currently in 7 selected centres).
Specific Hypotheses
We wish to test the following hypotheses (as suggested
by the IPMSSG [17]):
(i) Children who present with CIS are more likely to
develop MS than children who present with ADEM.
(ii) ADEM Children with prolonged steroid- depen-
dent events (≥ 3 months) are more likely to develop MS
than children with rapid recovery ADEM.
(iii) Children with multiphasic ADEM compared to
children with recurrent ADEM are more likely to
develop MS.
(iv) Children with recurrent ADEM are more likely to
develop MS than children with monophasic ADEM.
(v) MRI criteria (McDonald, KIDMUS) can be vali-
dated to distinguish between ADEM, ADEM variants,
CIS, and MS.
(vi) Identified future biomarkers with suggested prog-
nostic significance, can be tested against PUDDLS
outcomes.
(vii) Early treatment with disease modifying therapy in
relapsing CNS Inflammatory Demyelination, reduces
relapse rate and slows neurological disability progress.
(viii) Environmental risk factors can be identified for
children with first episode CNS inflammatory demyeli-
nation and MS.
New hypotheses will be added if suggested by publica-
tions by other centres prior to data analysis.
Methods/design
Case Definitions and Inclusion Criteria
Children (younger than 16 years) experiencing first epi-
sode of clinical neurological events consistent with site
specific inflammatory CNS demyelination and except in
Optic Neuritis confirmed with white matter changes on
MRI (table 1).
Exclusion criteria
1. Leukodystrophies (e.g., metachromatic leukodystro-
phy, adrenoleukodystrophy) or mitochondrial disease.
2. Proven CNS infection (e.g. bacterial meningitis,
herpes simplex encephalitis, Lyme disease, HIV).
3. Radiation/chemotherapy associated white matter
damage.
4. Condition fulfilling criteria for CNS connective tis-
sue disease e.g. lupus, vasculitis. The sole presence of
antibodies associated with CNS connective tissue dis-
eases is not sufficient for exclusion.
Relapses, MS, and Progression
A relapse is a new occurrence of neurological symptoms
that lasted > 24 hours and stabilized or resolved either
partially or completely. MS is defined in table 2 below.
Progression of MS is a continuous worsening of symp-
toms and signs for > 6 months, ± superimposed
Absoud et al. BMC Pediatrics 2011, 11:68
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relapses, either primarily (at onset of disease) or secon-
darily (after first relapse).
Design
PUDDLS ia a observational cohort study with sample
biobanking which will characterize the spectrum of CNS
demyelinating syndromes, their outcomes, and possible
progression to MS (Figure 2). Children will be recruited
over a 4 year and 6 month study period and followed
up. At recruitment an initial Case Report Form (CRF)
will be completed by the PI/Research Nurse/Research
Fellow. MRI copies and biological samples will be
archived. An environmenal questtionaire will be admi-
nistered by telephone interview within three months of
disease onset. Patient reported and proxy outcome ques-
ttionaires will be completed online at onset and at speci-
fied time intervals (Figure 3). At six months and one
year from onset, and then at yearly intervals, a follow-up
Figure 1 PUDDLS Flowchart with link to epidemiological study.
Table 1 PUDDLS Inclusion Criteria
Condition Inclusion Criteria
Acute
Disseminated
Encephalo-myelitis
(ADEM)
A polysymptomatic clinical event with acute/subacute onset that must include encephalopathy (behavioural change or
altered consciousness). (2) MRI Brain shows f multifocal lesions, predominantly involving white matter.
• Relapsing ADEM: symptoms or signs within 3 months of initial onset of ADEM.
IF a new event occurs ≥ 3 months later and ≥ 1 month after completing steroid treatment, it is defined as:
• Recurrent ADEM: recurrence of initial symptoms without involvement of new clinical areas.
• Multiphasic ADEM: New event, but involving new anatomical areas of the CNS.
Clinically Isolated
Syndrome
(CIS)
A first acute-clinical episode of CNS symptoms which may either be monofocal or multifocal, but does not include
encephalopathy (except in brainstem syndromes). The MRI will show area of white matter demyelination. These include:
Transverse myelitis: weakness and/or numbness of both legs +/- arms, usually with maximal deficits 1 week after
symptom onset supported by demyelination on MRI spine.
Brainstem, cerebellar, and/or hemisphericdysfunction, supported by demyelination on MRI.
Optic Neuritis
(ON)
Acute or subacute loss of vision and ≥ 1 of: relative afferent pupillary defect (unilateral cases), visual field deficit or
scotoma, impaired colour vision, optic disc oedema, or abnormal visual evoked potentials. MRI is not necessary for
diagnosis.
Neuro-myelitis Optica
(NMO)
Three of the following four criteria: i. Optic neuritis ii. Acute myelitis iii. Spinal MRI lesion extends over three or more
segments iv. NMO antibody testing is positive.
Absoud et al. BMC Pediatrics 2011, 11:68
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CRF will be completed in clinic. A telephone interview
will also be conducted at the same frequency to ask if
the patient has had a clinical relapse or hospital admis-
sion and to provide an opportunity to ask questions.
Any significant concerns will be referred back to the GP
or clinician in charge.
Patient recruitment and consent
Based on an expected incidence of 1-2/100,000 children,
each Centre is expected to recruit approximately 10-15
cases/year over the 5 year length of the study, with a
minimum of 6 months follow up. Children with CNS
Inflammatory Demyelination are seen by Paediatric
Neurologists with an interest in CNS Demyelination to
provide expertise in diagnosis and management. Patients
usually present to Neurologists’ attention via the follow-
ing routes:
- Presentation directly to Tertiary Centre.
- Referral from Paediatric DGH Consultant for admis-
sion or an outpatients opinion.
- MRI scans referred to weekly Tertiary Centre Neu-
roradiology meeting for an opinion (permission to
approach the clinician for referral will be obtained).
- Shared care or outreach clinic.
Patients will be ascertained via these available meth-
ods, and given or sent information leaflets before being
consented (minimum 24 hours) to take part in the
study. A website (http://www.childdemyelination.org.uk)
is set up to provide newsletters and information regard-
ing study progress, and up to date information on man-
agement directed at Paediatricians. If the patient or
carer requests referral, normal clinical follow up pat-
terns of care will be followed.
Currently in 7 centres, PIs will obtain consent from
families presenting to their centres. The Paediatric
Research Nurse at each site (0.1 WTE at each site, except
lead Centre [Birmingham] to have 0.3 WTE) or the
Research Fellow (Dr M Absoud) may also approach
families directly to obtain consent. Appropriate agree-
ments and contracts will be in place for the Research Fel-
low and Nurse as recommended by the National Institute
for Health Research. Patients will be asked to consent to:
- Taking part in the study and longitudinal follow up
via The National Health Service Information Centre
[Medical Research Information Service (MRIS)]
- Storage of Samples (CSF, DNA, serum)
- Obtaining MRI copies and information from Hospi-
tal notes
Table 2 Multiple Sclerosis definition
Multiple Sclerosis
(MS)
- Two or more non ADEM episodes of CNS demyelination separated in time (4 weeks) and space. For children aged > 10
years:
- Dissemination in space can be met if: MRI shows three of: 1) ≥ 9 white matter lesions or 1 gadolinium enhancing lesion, 2)
≥ 3 periventricular lesions, 3) One juxtacortical lesion, 4) an infratentorial lesion.
OR abnormal CSF (oligoclonal bands or elevated IgG index) with 2 lesions on the MRI (one in the brain).
- Dissemination in time can be met if: MRI shows new T2 or gadolinium enhancing lesions developing ≥ 3 months after
initial event.
Figure 2 The 5 major study themes are represented in flow the Figure below.
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- Sharing an anonymised dataset with the Interna-
tional Paediatric Study MS Group.
Data Collection and Outcome assessment
Data collection will take place at recruitment, 6 months
after initial event, annually after initial event, and during
clinical relapses (see Figure 3). Clinical follow ups for
patients affected with CNS inflammatory demyelinating
diseases will be part of clinical care, and no extra hospi-
tal visits will be required. Children and parents/carers
will be able to fill in questionnaires from a secure online
programme (Healthtracker TM). Access to a computer
with privacy will be made accessible if needed during
clinic visits. The Research Nurse will make contact with
the family at the designated follow up times, to ensure
they understand the research, ask about any relapses or
investigations the child might have had, and discuss
further queries.
The primary outcome measures will be (1) if the
patient developed a clinical relapse, and (2) a diagnosis
MS. Secondary outcome measures will include: Patient
reported and proxy Quality of life, disease impact, neu-
ropsychiatric & fatigue symptoms, conceptual & social
adaptive behavioural functioning skills, MRI criteria, and
objective EDSS disability scores (ie. EDSS > 5.5, patient
unable to walk without aid).
Case Report Forms (CRFs)
The CRFs have been adapted with permission after
consultation with the International Group. The initial
CRF (first episode) will be completed by the PI, the
Research Fellow, or the Research Nurse with assistance
from the PI. A condition specific targeted neurological
history (using a check box questionnaire) would take
place at the time of first demyelinating event. The
event would be classified as either ADEM, CIS, or MS
(see case definition). Data collected can broadly be
categorised to:
a. Basic demographic data (ethnicity, place of birth,
current residence).
b. Family history of MS or autoimmune disease.
c. Demyelinating symptoms and signs (using tick box
table).
d. Presence of behavioural disturbance or encephalo-
pathy (to distinguish ADEM from CIS) at time of
demyelinating event.
Figure 3 Data and Outcome Collection Schedule Summary.
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e. Information which might predict the subsequent
development of recurrent ADEM, multiphasic ADEM,
or MS, like details of the anatomic distribution (optic
nerve or spinal cord, monofocal or multifocal distribu-
tion), CSF findings, serological and neuroimaging
results.
f. Treatment (eg, steroids, immunoglobulins, intensive
care) given.
g. Information as to whether the risk of future MS was
given to the family.
h. Neurological examination, Kurtze EDSS scales, and
functional status.
For 6 month and annual outcome data, follow up
information will be obtained on neurological function
and further demyelinating events (if these have
occurred). We aim to collect 90% data within a window
period of one month on either side of the designated
follow up periods.
Healthtracker®; patient self report and proxy outcomes
PUDDLS will use Healthtracker® which is a sophisti-
cated, user-friendly, UK, and web-based assessment sys-
tem launched with Department of Health support in
2008. It comprises a suite of questionnaires and test
games for children and their carers, and not for investi-
gator use. These allow accurate measures of change
across a wide range of symptoms, side-effects, psycholo-
gical functions and quality of life. Assessments can be
home-based for convenience and lower costs. This helps
circumvent the many practical difficulties associated
with long-term assessment of chronic diseases.
Health related Quality of Life (QOL)
- Generic QOL: Pediatric Quality of Life Inventory TM;
Generates physical, psychological, and total score
○ Self report for ages 5-25 years.
○ Parent report for ages 2-25 years.
- Disease specific QOL: Multiple Sclerosis Impact
Scale-29 version 2 (MSIS-29 v2).
Generates physical, and psychological scores
○ Self report for children 5 years -adulthood.
○ Parent report.
Fatigue
- Pediatric Quality of Life Inventory TM; Multidimen-
sional Fatigue Scale
○ Self report for children 5-25 years
○ Parent report; for children 2- 25 years
Neuropsychiatric Symptoms
- Profile Of Neuropsychiatric Symptoms (PONS)
○ Self report for children 5-16 years
○ Parent report
Functioning; Adaptive behavioural skills
○ Adaptive Behaviour Assessment System II (ABAS II).
- Parent report for children 5 years -adulthood. Two
out of the three domains will be used:
(i) Conceptual skills: communication, functional aca-
demics, and self-direction skills areas
(ii) Social skills: Social, and leisure skills areas
Cognitive
○ Two Healthtracker online games played by children
aged 5-16 years that aim to measure memory, attention
and concentration. These are embedded in between
questionnaires.
○ Online D2 test game for participants aged 9 years-
60 years. The D2 Test measures processing speed and
quality of performance of individuals, allowing for a
neuropsychological estimation of individual attention
and concentration performance.
Environmental Questionnaire
One off telephone interview (30-45 minutes) with par-
ent/carer to be conducted during study period within
three months of disease onset if direct hospital contact
whilst inpatient has not been achieved. Only once
further funding is gained, case controls for administer-
ing only the environmental questionnaire will be ascer-
tained via a ‘buddy system’ to the child who is age and
sex matched. No other involvement of controls will be
required.
MRI criteria
Routine patient MRIs will be collected in order to apply
proposed criteria (such as McDonald, KIDMUS) that
the study team can validate against PUDDLS outcomes.
Data will be collected using a standardised data collec-
tion performa with agreed definitions designed by
Neuro-radiology collaborators (available on request).
MRIs will be randomly evaluated by one of four Neuror-
adiologists blinded to presentation and clinical features.
Inter-rater reliability will be assessed.
Biobank sample collection
Samples and Procedures
Additional informed consent will be obtained to store
sera, DNA, and CSF collected during routine clinical
care at first onset of a CNS demyelinating event, and
then at future hospital visits if clinical relapses occur.
This will be done in accordance with the Human Tissue
Act (HTA, 2004). Currently designated laboratories in
each of the seven establishments hold appropriate HTA
licences and would be responsible for storage:
(http://www.hta.gov.uk/licensingandinspections/listofli-
censedestablishments.cfm)
1. Alder Hey Children’s NHS Foundation Trust
2. Birmingham Children’s Hospital
3. Frenchay Hospital
4. Great Ormond Street Hospital
5. Guy’s & St Thomas’ Hospitals, Cellular Pathology
6. John Radcliffe Hospital
Absoud et al. BMC Pediatrics 2011, 11:68
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7. Nottingham University Hospitals NHS Trust
Sample collection, transport and storage will be
undertaken using standard SOPs and be based at colla-
borating centres as appropriate.
There will be no additional venepuncture or lumbar
puncture procedures for the child beyond those required
for routine clinical care. Informed consent will be
required, for extra volumes to be collected during these
procedures for the study. Residues of CSF and blood
already taken as part of the clinical management of the
patient, will also be used for future research investiga-
tions and to supplement the specimen archive. For each
patient at least one CSF sample and two blood samples
will be required. Clinicians will be encouraged to follow
existing guidelines for the investigation of CNS demyeli-
nating disorders (17,18) and as updated in the future.
Confidentiality
Samples will be stored pseudoanonymised in HTA
approved labs, and linked with the clinical data by the
unique PUDDLS number. Any information that is
likely to identify participants (such as name, address,
date of birth) will be removed from samples. Personal
identifiers are kept separately under strict control with
restricted access in secured cabinets, at the Institute of
Child Health, Birmingham Children’s Hospital in a
secure locked area. Access to data is limited to the
Chief and Principal Investigators. The study adminis-
trator at Birmingham Children’s Hospital will ensure
pseudo-anonymous tracking of the samples, solely for
the purposes of linkage once they are collected as
informed by the Principal Investigator. The location,
nature and date of samples will be recorded on the
database.
Future research
Separate funding will be sought for the biological/
genetic sample studies and a further five year longitudi-
nal follow up, once sufficient samples and clinical data
has been collected. The details of the studies are beyond
the scope of this protocol but we have identified future
potential studies of sufficient scientific validity to ethi-
cally justify the storage of human samples. Collabora-
tions with international experts and leaders in the field
will maximise yield of investigations, and ensure a thor-
ough review process:
The PUDDLS Biological Studies Steering Group will
consider any future studies, and follow the agreed
guidelines for study selection (available on request).
Once studies are deemed of sufficient quality, and
depending on the strand of study the group will colla-
borate with the experts in their fields and with the
International Paediatric Multiple Sclerosis Study Group
(IPMSSG).
Expected Numbers
Based on an expected incidence of 1-2/100,00 children,
the expected recruitment over the initial 5 year study
period is 400-450 cases (12-13/year in every Centre).
Statistics and data analysis
Descriptive statistics (with confidence intervals where
appropriate) will be used to summarise the key compo-
nents of the database. Univariate associations between
potential prognostics factors and potential confounders
and with MS diagnosis or other CNS demyelinating epi-
sodes; outcomes. These associations will be further
explored in logistic regression models that will allow for
control of confounding factors. Factors associated with
early occurrence of second episodes will also be
explored and Cox models will be used if the propor-
tional hazards assumption is met. Life table analysis
methods will be used to calculate primary outcome time
points. SPSS (v.17.0) statistical software will be used for
data analysis.
Research and development procedures
Research & Development (R&D) approval from each
participating NHS Trust will be obtained prior to
recruitment. Principal investigators will follow rules of
data protection ethics and confidentiality.
Longer term follow up
To ensure that long term outcomes of childhood
demyelinating disease can be identified by flagging
patients with their consent via the NHS Information
Centre (MRIS) and NHS Central Register which will
allow them to be traced in the future via their G.P.s. We
will consent patients for long term follow-up.
Data Handling and Integrity
• Each patient enrolled will be assigned a unique
PUDDLS study identification number. This number will
be used in all future correspondence between the study
centre and principal investigators.
• Principal investigators will be responsible for the
security of data at each local site according to their
employing authorities’ rules and regulations. Investiga-
tors will ensure that the study is conducted and data are
generated, documented and reported in compliance with
the protocol, and applicable regulatory requirements.
• Patient identifiable information (name and address)
will be sent to the study office on only one occasion
(initial case report form) by secure fax. The original
signed consent form to participate in the study will be
kept in the patient’s medical records unless required
otherwise by local regulations, and a copy kept securely
in the site file.
• At the central study office (ICH, Birmingham Chil-
dren’s Hospital), all patient identifiable study data will
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be stored in locked filing cabinets. Identifiable patient
data will be separated from the clinical data and linked
with a unique study code. Clinical data used for research
may also include patient identifiable data, e.g. date of
birth, sex, that are also important for the data analysis,
linkage during follow up, and to answer the research
questions. These cannot be removed from the question-
naire and will be stored for 30 years in secure archives
(MRC guidelines). Only pseudo-anonymised clinical data
only will be entered into the electronic study database
for analysis. Case report forms will be kept in the site
file in a secured locked cabinet, and a copy will be sent
to the Central study office at the Institute of Child
Health, Birmingham Children’s Hospital.
• Database Information
(i) Clinical Information
The research nurse, data administrator, and/or the
research fellow will enter and maintain the clinical
information for all study participants from within the
Institute of Child Health (ICH), Birmingham Children’s
Hospital. The database will be anonymised. CRFs will be
sent to the study team on paper. This has the added
benefit of providing consistency of data entry, allowing
for more complete and accurate set of data for long
term analysis. This database will use the PUDDLS code
only. The data base will be password protected, backed
up by the ICH server backup daily, and encrypted for
added protection. The database will be accessed accord-
ing to Trust policies and procedures.
(ii)Healthtracker TM
Healthtracker is hosted with Rackspace on a single
server running the Microsoft Windows Server 2003
Standard Edition operating system. Rackspace ensures
the server is continuously updated and has all the latest
service packs and security patches. The server itself
houses a Dual-Core AMD Opteron processor running at
2.20 GHz with 4.0 GB of RAM. It has three 73 GB SCSI
hard drives in a RAID 5 configuration offering 140 GB
of usable storage. The server acts as both the web and
database server running Internet Information Services
(IIS) and SQL Server 2005 Standard Edition.
Both the admin and non-admin websites use SSL 128
bit encryption to ensure data is securely encrypted
between requests. The websites are written in C# and
run under the Microsoft .Net 2.0 framework. HTML
and cascading style sheets are used in both sites to
apply common styling. All database transactions are per-
formed via stored procedures (there is no in-line SQL).
Flash is used to provide some questionnaire and game
content to the child portion of the non-admin website.
XML web services are used to send and receive infor-
mation to and from these components. All data in the
system is stored in a single SQL Server database and
therefore can be exported in any format facilitated by
SQL Server. Alternatively custom exports can be
written.
Healthtracker (HT) Results are generated in real time
and can reflect symptom trends/treatment efficacy/or
changes over time. The program has been designed with
the ability to analyse large amounts of longitudinal data
with inbuilt real-time Bayesian/Neural Net algorithms.
This system allows testing of hypothesis as new data
comes in. The online presentation of HealthTracker has
already meant that rapid acquisition of data for norm-
ing, or comparing new measures with existing ones is
possible. Non-linear mixed effects modelling will be
used to generate estimates of expected recoveries. Data
from HT will also be exported via an excel spreadsheet
for the research team to analyse. Item analysis of ques-
tionnaires will be via Rasch analysis, utilising the WIN-
STEPS TM statistical software.
• Data protection, security and confidentiality will be
implemented according to the UK Data Protection Act
1998 and each Trust’s own Information Governance
Policy.
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